Metabolic-epigenetic reprogramming of airway fibroblasts by K + N therapy suppresses IL-33 and ameliorates allergic asthma.
BACKGROUND Allergic asthma is a prevalent Th2-driven chronic inflammatory airway disease. While lung fibroblasts and fibroblast-derived IL-33 critically regulate airway inflammation, the fibroblast-specific role of IL-33 and the therapeutic mechanism of the immune regulatory small-molecule KQS1 and nicotinamide (K + N)...